A B S T R A C T Oxidation of the side chain of 5,3-cholestane-3a,7a,12a-triol was studied in a patient with cerebrotendinous xanthomatosis (CTX) and in control subjects, using various subcellular fractions of liver homogenate and a method based on isotope dilution-mass spectrometry.
cholestane-3a,7a,12a-triol was studied in a patient with cerebrotendinous xanthomatosis (CTX) and in control subjects, using various subcellular fractions of liver homogenate and a method based on isotope dilution-mass spectrometry.
In the control, 5p8-cholestane-3a,7a,12a-triol was converted into 5f3-cholestane-3a,7a,12a,26-tetrol and 3a,7a,12a-trihydroxy-5,8-cholestanoic acid by the mitochondrial fraction, and into 5,8-cholestane-3a,7a,12a,- 25 -tetrol by the microsomal fraction.
In the CTX patient, liver mitochondria were completely devoid of 26-hydroxylase activity. The same mitochondrial fraction catalyzed 25-hydroxylation of vitamin D3.
The microsomal fraction of liver of the subject with CTX contained more than 50-fold the normal amount of 5f3-cholestane-3a,7a,12a-triol.
The basic metabolic defect in CTX appears to be a lack of the mitochondrial 26-hydroxylase. The excretion in the bile of 5,p-cholestane-3a,7a,12a,25-tetrol and 5f3-cholestane-3a,7a,12a,24a,25-pentol observed in CTX patients may be secondary to the accumulation of the major substrate for the 26-hydroxylase, i.e., 5,8- cholestane-3a,7a,12a-triol, and exposure of this substrate to the normally less active microsomal 25-and 24-hydroxylases. It is concluded that the major pathway in the biosynthesis of cholic acid in human liver involves a mitochondrial C27-steroid 26-hydroxylation. INTRODUCTION From a great number ofin vivo and in vitro experiments in humans as well as in rats, evidence has accumulated that in the biosynthesis of bile acids, the normal degradation of the cholesterol side chain starts with a 26-hydroxylation,l followed by oxidation of the hydroxyl group to yield 3a,7a-dihydroxy-5,0-cholestanoic acid and 3a,7a,12a-trihydroxy-5,8-cholestanoic acid (5-10; Fig. IA ). The mitochondrial fraction of both human and rat liver contains a 26-hydroxylase, which is active towards several 7a-hydroxylated C27-steroids (11, 12) . In rat liver (12, 13) the microsomal fraction is able to catalyze 26-hydroxylation of some C27-steroids. In both rat (12) and human (11) liver, the microsomal fraction is able to catalyze the introduction of hydroxyl groups also in the 23-, 24-, and 25 activities were originally believed to be of minor patients with the rare lipid storage disease cerebrophysiological significance (12) . tendinous xanthomatosis (CTX), were 5f3-cholestaneIn 1974, however, Setoguchi et al. (14) showed that 3a,7a,12a,25-tetrol and 5,8-cholestane-3a,7a,12a,24,25--10% of the total sterols excreted in feces of three pentol. In later studies, this group of researchers
Absence of Steroid 26-Hydroxylase in Cerebrotendinous Xanthomatosis presented evidence that in the liver of healthy control subjects as well as in the liver of CTX patients, enzymes are present that are able to catalyze formation of cholic acid from 5p3-cholestane-3a,7oa,12a,25-tetrol ( higher in the microsomal fraction of liver of a control subject than in the corresponding fraction of a CTX patient (16, 17) . It was concluded that the major metabolic defect in patients with CTX is a relative lack of 24,8-hydroxylase activity. On the basis ofthese findings, it was further suggested that the pathway to cholic acid, involving a 25-hydroxylation, may be the major one in normal man (15, 16) . However, the possibility that the pathway involving a 26-hydroxylation is the main route could not be excluded (15) .
In the present work we have investigated the latter possibility and we show that the mitochondrial fraction from the liver of a patient with CTX was completely devoid of 26- 5,f-Cholestane-3a,7a,12a-triol and 5f8-cholestane-3a,7a,12a,-26-tetrol were synthesized as described (13) . 3a,7a,12a-Trihydroxy-5,8-cholestanoic acid was obtained from alligator bile (13) . This acid isolated from this species appears to be the 25R-isomer (19, 20) . The alkaline conditions used in the isolation procedure might, however, to some extent change the stereospecificity at C-25. Most probably the 3a,7a,12a-trihydroxy-5/8-cholestanoic acid synthesized in human liver has the 25R-configuration (21) . In any case, the 25R-and 25S-isomers are not separated under any of the chromatographic conditions used in the present work.
Tritium-labeled steroid. 5,8-[7_3-3H]Cholestane-3a,7a,12a-triol (7 Ci/mol) was synthesized as described (13) .
Deuterium-labeled steroids. 25-Hydroxy[262H]vitamin D3 was synthesized as described (22 (23) . This compound, 20 mg, was refluxed in 5 ml of CH302H and 1 ml of 2H20 together with 12 mmol NaOH for 24 h. The deuterated solvents were obtained from Merck AG (Darmstadt, West Germany) and had a purity of >99% with respect to 2H. The mixture was then diluted with 2H20, acidified with 2HCI (Merck AG, 99% pure with respect to 2H) and extracted with diethyl ether. The ether phase was washed with 2H20 until neutral. After evaporation of the solvent in vacuo, the residue was treated with 5 ml of CH302H and 10 mg of NaB2H4 (Merck AG, 99% pure with respect to 2H) for 1 h at room temperature. After dilution with 2H20 and acidification with 2HCI, the mixture was extracted with ether as above. The reduced material in the ether phase was purified by preparative thin-layer chromatography, using ethyl acetate as solvent. Crystallization in methanol-water gave 5.7 mg of white needles. The material was pure as judged by thin-layer chromatography (ethyl acetate as solvent) and gas chromatography of the trimethylsilyl ether using a SE-30 column. A mass spectrum (LKB 9000, LKB Instruments, Inc., Stockholm, Sweden) of the trimethylsilyl ether of the compound confirmed the identity and showed that the material was a mixture of tetraand pentadeuterium labeled 5/3-cholestane-3a,7a,12a-triol.
Thus the peaks at the mass/charge ratio (mle) 546, mle 456, mle 366, and mle 253 in the mass spectrum ofthe trimethylsilyl ether of unlabeled 5f3-cholestane-3a,7a,12a-triol were shifted to mle 551, mle 461, mle 371, and mle 258 in the mass spectrum of the deuterium-labeled compound (Fig. 2 ).
2H5-Labeled 5/8-cholestane-3a,7a,12a-triol was then incubated with the microsomal fraction of a rat liver homogenate (11, 13) . The products, 2H,-labeled 5,8-cholestane-3a,7a,12a,-25-tetrol and 5,8-cholestane-3a,7a,12a,26-tetrol were isolated by thin-layer chromatography (12, 13 (Fig. 3) .
In each incubation assay, a fixed amount of the thin-layer chromatographic fraction containing 2H5-labeled 5,f-choles- m/e FIGURE 2 Partial mass spectrum of trimethylsilyl ether of unlabeled (upper spectrum) and 2H5-labeled 5,1-cholestane-3a,7a,12a-triol (lower spectrum). reference value 0.9+0.2 [25] ) and of excess cholestanol in a tendon xanthoma (17% of the sterol fraction). Cholestanol was separated from cholesterol by thin-layer chromatography of lipid extracts (26) of the xanthoma and serum on plates coated with 20% AgNO3 (27) . Quantitative analyses by gas liquid chromatography (Varian 2100 instrument, Varian Associates, Palo Alto, Calif.) were performed after treatment with trifluoroacetic anhydride, using 3% QF 1 columns at 220°C, and a-cholestane as internal standard. The identity of cholestanol was established by mass spectrometry (Varian CH7 instrument). The spectrum was the typical one (28) with peaks at 388, 373, 355, 234, 233, and 215.
A specimen of bile was analyzed in 1976 by Dr. Gerald Salen. The relative contents of bile acids and bile alcohols were: 5f3-cholestane-3a,7a,12a,triol 1%, 5,8-cholest-25-ene3a,7a,12a-triol 4%, 5,8-cholestane-3a,7a,12a,25-tetrol 32%, cholic acid 41%, deoxycholic acid 2%, chenodeoxycholic acid 1%, and unidentified bile alcohols 19%. As compared with normal bile (14, 25) the most striking findings were thus a deficiency in chenodeoxycholic acid (normal amounts 40-45%), and large amounts of bile alcohols (normally not detectable).
In 1978, the patient was admitted to the hospital (Haukeland sykehus, Bergen, Norway) for acute cholecystitis. Because of numerous gallstones it was decided to perform a cholecystectomy. Liver function tests were normal. With the informed consent of the patient and her family, a liver biopsy (1.4 g) was removed during the operation in June 1979.
Control subjects. Normal human liver material was made available from a renal transplant donor, a 32-yr-old man, dead according to officially adopted Norwegian criteria. Needle biopsies (30-35 mg) taken routinely during abdominal surgery were obtained from six patients free of liver diseases.
Preparation of subcelltular fractions of liver biopsies.
Immediately after the biopsies were taken, they were put on ice-cold 0.25 M sucrose, 25 mM Mops buffer, pH 7.4, and homogenized in a Potter-Elvehjem homogenizer. Mitochondria were prepared without delay as described (29) with the exception that they were washed only twice. Microsomes were prepared from the postmitochondrial The reaction was started by the addition of substrate (0.4-12 ,g of tritium-labeled 513-cholestane-3ca,7a,12a-triol in 10 ,ul of ethanol) and allowed to proceed for 60 min at 37°C under oxygen. The reaction was terminated by the addition of 0.1 ml 1 N HCI. When 2H5-labeled 518-cholestane3a,7a,12a-25 and 26-tetrols were used as internal standards, these were added together with the HCI.
After extraction with ethyl acetate (31) the solvent was evaporated under N2 and the residue redissolved in 100-300 ,ul of methanol. Aliquots of the samples were subjected to HPLC (SP 3500 B liquid chromatograph, Spectra-Physics, Inc., Santa Clara, Calif.) using a Spherisorb ODS column (4.6 x 250 mm, particle size 5 ,um), and 13% H20 in methanol as eluting solvent (1 ml/min) (32) . The collected fractions (1/min) were counted in a Packard Tri-Carb liquid scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.) and the rate of conversion of 5,8-cholestane-3a,7a,12a-triol was calculated from the distribution of the radioactivity. Any loss of highly polar material to the water phase (<1% of the total radioactivity was recovered in this phase) was not taken into account. chromatography-mass spectrometry (GC-MS), using a 1.5% SE-30 column at 2800C (LKB 9000 instrument, equipped with a multiple ion detector). The multiple ion detector was focused on the ion at mle 456 and on the ion at rne 461 (corresponding to M -2 x 90 fragment) (Fig. 2) . The ratio between the two tracings were strictly linear with increasing amounts of unlabeled 5#-cholestane-3a,7a,12a-triol in the presence of a fixed amount of 2H,-labeled 5,6-cholestane-3a,-7a,12a-triol (Fig. 4A) . The amount of unlabeled 5,f-cholestane-3a,7a,12a-triol was calculated from the ratio between the two tracings and the standard curve. The steroids were extracted as described above and, without further purification, converted into trimethylsilyl ether, and subjected to analysis by GC-MS. The multiple ion detector was focused on the ion at rne 544 and at rne 549 (Fig. 3) . The amount of unlabeled 5,8-cholestane-3a,7a,12a,- Because of a lack of synthetic material no standard curve could be produced in this case, but the reasonable assumption was made that the ratio between unlabeled 25-tetrol and 2H5-tetrol was the same as the ratio between the two peaks occurring in the two tracings. A ratio of 1.0 between the height of the peak at rne 544 and the height of the peak at m/e 549 was thus assumed to correspond to 120 ng ofunlabeled 5,8-cholestane-3a,7a,12a,25-tetrol.
In the assay of 3a,7a,12a-trihydroxy-5,8-cholestanoic acid, the lipid extract containing the mixture of 2H5-labeled 25- tetrol and 26-tetrol was methylated with diazomethane and converted into the trimethylsilyl ether before analysis by GC-MS. The detector was focused on the ion at n/e 544 (to follow the 2H5-labeled 26-tetrol) and on the ion at rne 500 (Fig. 4C) . When the amount of unlabeled 3a,7a,12a-trihydroxy-5,8-cholestanoic acid was <200 ng, the ratio between the peak heights deviated from linearity, however, and the quantitation in this range must be considered as approximate.
In the assay of 25-hydroxylation of vitamin D3 by the mitochondrial fraction of human liver, the assay conditions used were identical to those used for assay of26-hydroxylation of 5f8-cholestane-3a,7a,12a-triol ( The rates of formation of these more polar products were markedly higher with the subcellular fractions from the liver of the control subject than from the CTX patient (Fig. 5) . In particular, the hydroxylation activity of the mitochondrial fraction from the CTX subject was reduced to near the detection limit.
From the substrate saturation curves (Fig. 5 ) the Vmax and Km values for the hydroxylase activities of the various fractions could be determined and the results are summarized in Table I . The most striking feature is the reduction in the Vmax for the mitochondrial hydroxylation activity of the CTX subject to 0.5% of that of the control. The microsomal activity of the CTX patient is apparently lowered in that it amounted 0.5 to only 27% of that ofthe control (see below). Identical Km values were found for the homogenate and the mitochondria from the control subject, whereas the values were identical for the homogenate and the microsomes from the CTX patient (Table I) . These findings certainly reflect the importance ofthe different subcellular fractions to the overall hydroxylation activity of the homogenates, the mitochondrial fraction being more important in the control whereas the microsomal fraction is dominant in the CTX patient.
Conversion of 5,¢cholestane-3a,7a,12a-triol into 5f3-cholestane-3a,7a,12a-,25-tetrol, 5,3-cholestane3a,7a,12a,26-tetrol, and 3a,7a,12a-trihydroxy-5,3-cholestanoic acid by subcellular fractions of normal liver and liver from the CTX patient. In Fig. 6A incubation of 5,3-cholestane-3a,7a,12a-triol with whole homogenate of normal human liver. Peaks were obtained both in the tracing at mnle 544 (corresponding to unlabeled 25-tetrol and 26-tetrol) and in the tracing at mile 500 (corresponding to unlabeled 3a,7a,12a-trihydroxy-5,/-cholestanoic acid). However, there was a significant peak corresponding to unlabeled 5,3-cholestane-3a,7a,12a,25-tetrol.
The results of the different incubations are summarized in Table II . In consonance with the previous work (11), the normal human liver microsomes catalyzed 25-hydroxylation of 5,3-cholestane-3a,7a,12a-triol, but not 26-hydroxylation. The microsomal fraction from the CTX patient had a somewhat lower capacity to 25-hydroxylate 5,8-cholestane-3a,7a, 12a-triol than the microsomal fraction from the control subject. The mitochondrial fraction from the control subject catalyzed conversion of 5,8-cholestane-3a,7a,-12a-triol into both 5,3-cholestane-3a,7a,12a,26-tetrol and 3a,7a,12a-trihydroxy-5,8-cholestanoic acid at high rates. The mitochondrial fraction from the CTX patient, however, was completely devoid of such activity.
The mitochondrial and microsomal fractions were isolated and assayed for 25-and 26-hydroxylase activity in oinly one control subject. Whole homogenate from seven control subjects were assayed for these activities. In all cases 26-hydroxylation was detected, but the rate varied considerably (mean 0.81, and range 0.33-2.45 nmol x mg-' x h-1) between the different preparations.
The lack of 26-hydroxylase activity in the mitochondrial fraction of the CTX patient might theoretically be the result of inactivation of mitochondrial fraction during preparation. This possibility was excluded, however, by incubation of the mitochondrial fraction from the CTX patient with 10 ,ug of vitamin D3 under essentially the same incubation conditions as those used for assay of 26-hydroxylation of 5,3-cholestane-3a,7a, 12a-triol. A significant conversion into 25-hydroxyvitamin D3 was observed (6 pmol x mg protein-' x h-1). With the microsomal fraction a conversion of 3 pmol x mg protein-x h-1 was found. The considerably lower specific activity with this fraction excludes the possibility that the mitochondrial activity was the result of microsomal contamination.
Accumulation of .5a-cholestane-3a,7a,12a-triol itn the liver of the CTX patient. By using 2H5-labeled 5,8-cholestane-3a,7a,12a-triol as internal standard, the amount of unlabeled 5,8-cholestane-3a,7a, 12a-triol was measured in whole homogenate and mierosomal fraction from liver of two control subjects and the CTX patient. In Fig. 7 , the mass fragmiienitographic recordings are shown that were obtainedl in the analysis of trimethylsilyl ether of purified extract from microsomal fraction from liver of the control subject (A) and the CTX patient (B). The tracing at tn/le 456, corresponding to unlabeled 5fl-cholestane3a,7a,12a-triol, gave a much higher peak in the analysis of the material from the CTX patient than in the analysis of the material from the control subject.
The exact amount of unlabeled 5,8-cholestane-3a,7a,-12a-triol in the different subcellular fractions were calculated, using the standard curve shown in Fig. 4A . The results are summarized in Table III . The amount of 5,8-cholestane-3a,7a,12a-triol was -50-fold higher in the microsomal fraction and in the whole homogenate from the liver of the CTX patient as compared with the two control subjects. Included in Table III 5,8-cholestane-3a,7a, 12a,25-tetrol determined in the blank incubations with the homogenate and the microsomal fractions. Again, much higher levels were detected in the fractionis from the CTX patient than from the control subject. The lower amount of the tetrol relative to the triol in the microsomes from the CTX patient but not in the homogenate should be noted. The lower coinversion of tritium-labeled 5fl-cholestane-3a,7a,12a-triol to more polar products by the microsomal fractioni of the CTX patient than by that of the control subject (Table I) (Table III) .
In a previous work, we observed that 5,8-cholestane3a,7a-diol was 25-hydroxylated by human liver microsomes to a considerably lower extent than was 5,3-cholestane-3a,7a,112a-triol (11) . Thus more cholic acid relative to chenodeoxycholic acid will probably be formed by the 25-hydroxylase pathway. If the 25- hydroxylase pathway is of importance under normal conditions, and the basic defect in CTX patients is a relative deficiency of the enzyme catalyzing 24- hydroxylation of 5,f-cholestane-3a,7a,12a, 25-tetrol, it would be expected that cholic acid biosynthesis should be more affected than the biosynthesis of chenodeoxycholic acid. In contrast, however, it has been reported that the production of chenodeoxycholic acid in patients with CTX is decreased more than the production of cholic acid (25) and a deficiency of chenodeoxycholic acid in the bile was found also in our patient. This is in accord with the contention that the basic metabolic defect in CTX is a lack of the 26-hydroxylase. It is believed that the major substrate for the mitochondrial 26-hydroxylase in the biosynthesis of chenodeoxycholic acid is 5/3-cholestane3a,7a-diol. If this compound accumulates in patients with CTX, it will be exposed to the action of the 12a-hydroxylase to a greater extent than in normal subjects (37, 38) . The consequence will be an even higher accumulation of 5,8-cholestane-3a,7a,12a-triol, which leads to a shift towards biosynthesis of cholic acid.
In addition to the results presented here, there are some other indications in the literature that the 26-hydroxylase pathway normally is more important than the 25-hydroxylase pathway. Thus Cronholm and Johansson (12) have reported that tritium-labeled 5,8-cholestane-3a,7a,12a,26-tetrol was converted into cholic acid in a bile fistula rat much more efficiently than was tritium-labeled 5,3-cholestane-3a,7a,12a,25-tetrol (12) . Very recently the same experiment was repeated in human patients with a biliary fistula (39) . Also in this case, labeled 518-cholestane-3a,7a,-12a,26-tetrol was converted into cholic acid much more efficienitly thalni was labeled 5A-cholestane3a,7a, 12a,25-tetrol.
In conclusioni, the presented results and the above considerations are all in agreement with the view that the 26-hydroxylase pathway is normally the major one in the biosynthesis of both cholic acid and chenodeoxycholic acid in man. In patients with CTX however, the 25-hydroxylase will partly compensate for the lack of the 26-hydroxylase and thus become of major importance in the biosynthesis of bile acids.
